Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.67 |
| ▸ | MAPT | P10636 | 2/20 | 0.67 |
| ▸ | LMNA | P02545 | 3/20 | 0.64 |
| ▸ | HPGD | P15428 | 1/20 | 0.64 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.64 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.62 |
| ▸ | THRB | P10828 | 1/20 | 0.62 |
| ▸ | POLB | P06746 | 1/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.56 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.56 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.56 |
| ▸ | AGER | Q15109 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11577296 | 0.87 | LMNA (0.64) | ALDH1A1MAPTLMNAHPGDMAPK1 | |
| SCHEMBL29678332 | 0.85 | LMNA (0.66) | ALDH1A1MAPTLMNAHPGDMAPK1 | |
| SCHEMBL4003436 | 0.85 | LMNA (0.66) | ALDH1A1MAPTLMNAHPGDMAPK1 | |
| SCHEMBL14085811 | 0.85 | ALDH1A1 (0.67) | ALDH1A1MAPTLMNAHPGDMAPK1 | |
| SCHEMBL4210079 | 0.83 | LMNA (0.64) | ALDH1A1MAPTLMNAHPGDMAPK1 | |
| SCHEMBL28947962 | 0.83 | MAPT (0.65) | ALDH1A1MAPTLMNAHPGDMAPK1 | |
| SCHEMBL15684207 | 0.83 | KDM4E (0.70) | ALDH1A1MAPTLMNAHPGDMAPK1 | |
| SCHEMBL2169180 | 0.82 | MEN1 (0.68) | HPGDKDM4EPOLBKMT2A | |
| SCHEMBL8334831 | 0.81 | KDM4E (0.69) | ALDH1A1MAPTLMNAHPGDMAPK1 | |
| SCHEMBL2093177 | 0.80 | MAPT (0.71) | ALDH1A1MAPTLMNAHPGDMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7790726-B2 | Monocyclic and bicyclic compounds and methods of use | CHEMOCENTRYX, INC. (US) | 2010-09-07 | — | — | US | disclosed |
| US-7790726-B2 | Monocyclic and bicyclic compounds and methods of use | CHEMOCENTRYX, INC. (US) | 2010-09-07 | — | — | US | disclosed |
| US-7790726-B2 | Monocyclic and bicyclic compounds and methods of use | CHEMOCENTRYX, INC. (US) | 2010-09-07 | — | — | US | disclosed |
| US-7786157-B2 | OXO-imidazolidines as modulators of chemokine receptors | CHEMOCENTRYX, INC. (US) | 2010-08-31 | — | — | US | disclosed |
| US-7786157-B2 | OXO-imidazolidines as modulators of chemokine receptors | CHEMOCENTRYX, INC. (US) | 2010-08-31 | — | — | US | disclosed |
| US-7786157-B2 | OXO-imidazolidines as modulators of chemokine receptors | CHEMOCENTRYX, INC. (US) | 2010-08-31 | — | — | US | disclosed |
| EP-1931348-A4 | MONOCYCLIC AND BICYCLIC COMPOUNDS AND METHODS OF USE | CHEMOCENTRYX INC (US) | 2009-08-12 | — | — | EP | disclosed |
| US-20080269280-A1 | OXO-IMIDAZOLIDINES AS MODULATORS OF CHEMOKINE RECEPTORS | CHEMOCENTRYX, INC. (US) | 2008-10-30 | — | — | US | disclosed |
| US-20080269280-A1 | OXO-IMIDAZOLIDINES AS MODULATORS OF CHEMOKINE RECEPTORS | CHEMOCENTRYX, INC. (US) | 2008-10-30 | — | — | US | disclosed |
| US-20080269280-A1 | OXO-IMIDAZOLIDINES AS MODULATORS OF CHEMOKINE RECEPTORS | CHEMOCENTRYX, INC. (US) | 2008-10-30 | — | — | US | disclosed |
| EP-1931348-A2 | MONOCYCLIC AND BICYCLIC COMPOUNDS AND METHODS OF USE | ChemoCentryx Inc (US) | 2008-06-18 | — | — | EP | disclosed |
| US-20070066583-A1 | Monocyclic and bicyclic compounds and methods of use | CHEMOCENTRYX, INC. (US) | 2007-03-22 | — | — | US | disclosed |
| US-20070066583-A1 | Monocyclic and bicyclic compounds and methods of use | CHEMOCENTRYX, INC. (US) | 2007-03-22 | — | — | US | disclosed |
| US-20070066583-A1 | Monocyclic and bicyclic compounds and methods of use | CHEMOCENTRYX, INC. (US) | 2007-03-22 | — | — | US | disclosed |
| WO-2007022257-A2 | MONOCYCLIC AND BICYCLIC COMPOUNDS AND METHODS OF USE | CHEMOCENTRYX, INC. (US) | 2007-02-22 | — | — | WO | disclosed |
| WO-2007022257-A2 | MONOCYCLIC AND BICYCLIC COMPOUNDS AND METHODS OF USE | CHEMOCENTRYX, INC. (US) | 2007-02-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070066583-A1 | Monocyclic and bicyclic compounds and methods of use | CCR1, CCR3, CCR4 | ALDH1A1 1533/4885MAPT 3597/4885LMNA 2708/4885 |
| US-20080269280-A1 | OXO-IMIDAZOLIDINES AS MODULATORS OF CHEMOKINE RECEPTORS | CCR1, CCR3, CCR4 | ALDH1A1 2544/4885MAPT 4486/4885LMNA 4587/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.